where CI is confidence. But economically this is telling you the cost you must incur (N) for a given level of quality (inputs into f, including MDE).
That has economic value, but is not really how studies are done or items are purchased. Consumers don't say, I have to have a car of this quality, just tell me what to spend. They see a vector of (quality, price) pairs & choose pair that maximizes U s.t. their budget constraint.
Econometricians are consumers of info. They should behave the same way. Should examine (MDE,N) pairs & choose one that is optimal. If we assume the unit price of N is p, then I can get a sequence of costs C associated with qualities MDE: (C(N),MDE).
So why do I say, report MDE's rather than N? The reality is very few of us pay out-of-pocket for studies. (Sometimes we have a grant budget for multiple studies. But my experience has been 1 budget=1 study.) But if I have a fixed budget, then C(N) is fixed, so N is fixed.
What I want to know is MDE = g(CI,design,N).
BTW, you could say show me the whole set (MDE,CI,design) compatible with affordable N. But anyone going through peer review kinda thinks CI & design are fixed too. ;)
Also, MDE rather than N be the focus. Eg while I prefer a car w heated seats (being from Chicago), a car w/o heated seats has value. Usual sample size calcs seem to suggest if you can't hit N*, don't bother doing the study (or suggests the journal shouldn't publish your results).
Its true people can on the backside manipulate MDE or study goals. But that is not exactly what statisticians really want you to do when they ask you to do sample size calcs. Plus, we shouldn't be ashamed of those tradeoffs. Instead we should be open & ration about them.
All this said, I can see the value of an economics literature that continues trying to work with
N = f(CI,design,MDE)
It would be great to see the price associated with causal inference (design). The debate over the value of RCTs is an example of this dort of analysis.
Endnotes:
1/This is'nt a novel idea. Logic flows from work on data markets, the economics of sample size. Eg Philipson, Desimone, etc.
2/Seems like this could be a good approach for grant funder to take. Think of it as evaluation evaluation as opposed to impact evaluation.
I want to highlight this MR post by @ATabarrok. It has AFAIK a novel approach to trials that warrants serious discussion: release a drug & randomize access via lottery. Then compare outcome across ppl that won lottery and those who lost. Like the Oregon Health Ins Experiment.
If we do this, we may want to subsidize the price, so that demand for the lottery is high. This may also address ethical issues.
But there are some important issues with this approach. Not all insurmountable. Here is a first cut.
1/Selection. Ppl who are randomized to no access will get other treatment. Some will take nothing, others will take another conventional treatment if available.
But this is a problem with existing trials. I noted an old article on selection into RCTs.
TLDR: The value of a vaccine, & thus your distribution priorities, depends on the counterfactual. If CF is no/delayed vaccine & *suppression* (eg lockdown), main benefit of vaccine is economic activity. If CF is no/delayed vaccine & *no suppression*, main benefit is health. 2/20
In the former CF, you prioritize the most productive people. In the latter CF, you would prioritize people at greatest risk of health harm from COVID. 3/20
CAN YOU HELP SLUMS WITH HANDWASHING?
This is an urgent request form NGOs working to stop COVID in Indian slums. Details of problem in THREAD. Summary: we need solution that slums can implement themselves w/ reused water. Please retweet to increase eyeballs. 1/ @vandanagoyal01
Handwashing requires water & soap. Both are in short supply in slums cuz they usually don't have water pipes. Govt sometimes sent water tankers, but those have slowed. 2/ @adamschilton@tariqthachil@adam_m_auerbach
We can't create new handwashing stations. This takes time to scale w/o a lockdown. With India's 21 day lockdown, definitely cannot ship them there. Plus, they require water. 3/ @pritika13@nebuer42
A key issue in the cost-benefit analysis on #COVID19 is how ending suppression would affect the economy*. I assume main mechanism is through *voluntary* social distancing. What is the best estimate of that? 1/4 @ATabarrok
*NOTE: Release is terrible for health.
Is there an estimate of prevalence response elasticity (using econ epi terms) for COVID? If the policy switched, should we assume that there would be a comms strategy to reduce fear? 2/4
A 2nd reason release may hurt the economy is death. But those effects are mitigated because most of those who pass are above 70 (sadly). There will be absenteeism among young. 3/4
Thinking about suppression v. mitigation for India. One issue that came up is breadth of immunity & future corona flare-ups. Suppression relies on vaccine acquired immunity (VAI); mitigation on natural immunity (NI). This may have implications for comparing loss of life. 1/6
By immune breadth I mean the⬇️in probability of infection/harm as you ⬆️ distance between current & next strain in genetic/antigenic space. 2/6
For old time gamers, think of it as the radius of the explosion when you fire at incoming missiles in Missile Command: bigger breadth is better cuz you knock out more missiles. The bigger the immune breadth, the more protected you are against future strains.* 3/6